On these grounds, clinical trials to evaluate the efficacy of recombinant IL‐7 to restore lymphocyte counts in COVID‐19 patients have been registered (NCT04407689, NCT04379076 and NCT04426201) (Figure 2C, Table 1). Here, IL7 is linked to COVID-19.